287 related articles for article (PubMed ID: 29222300)
1. Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies.
Kumar S
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):518-524. PubMed ID: 29222300
[TBL] [Abstract][Full Text] [Related]
2. Salvage therapy of multiple myeloma: the new generation drugs.
Romano A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Di Martina V; Schinocca E; La Fauci A; Parrinello NL; Chiarenza A; Di Raimondo F
Biomed Res Int; 2014; 2014():456037. PubMed ID: 24967371
[TBL] [Abstract][Full Text] [Related]
3. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt H; Ashcroft J; Szabo Z; Garderet L
Ann Hematol; 2019 Jan; 98(1):1-18. PubMed ID: 30470875
[TBL] [Abstract][Full Text] [Related]
4. Immune-based therapies in the management of multiple myeloma.
Zanwar S; Nandakumar B; Kumar S
Blood Cancer J; 2020 Aug; 10(8):84. PubMed ID: 32829378
[TBL] [Abstract][Full Text] [Related]
5. How is patient care for multiple myeloma advancing?
Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
[TBL] [Abstract][Full Text] [Related]
6. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Varga C; Laubach JP; Anderson KC; Richardson PG
Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in understanding multiple myeloma.
Hari P
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):267-271. PubMed ID: 28633036
[TBL] [Abstract][Full Text] [Related]
8. Emerging agents and regimens for multiple myeloma.
Yang Y; Li Y; Gu H; Dong M; Cai Z
J Hematol Oncol; 2020 Nov; 13(1):150. PubMed ID: 33168044
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
10. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
13. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma : recent progress in diagnosis and treatment.
Chou T
J Clin Exp Hematop; 2012; 52(3):149-59. PubMed ID: 23269074
[TBL] [Abstract][Full Text] [Related]
15. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
16. Management of multiple myeloma in the relapsed/refractory patient.
Sonneveld P
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):508-517. PubMed ID: 29222299
[TBL] [Abstract][Full Text] [Related]
17. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
18. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
[TBL] [Abstract][Full Text] [Related]
19. BCMA-targeting approaches for treatment of multiple myeloma.
Chen Y; Nagarajan C; Tan MS; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):28-36. PubMed ID: 32955181
[TBL] [Abstract][Full Text] [Related]
20. Cellular immunotherapy in multiple myeloma.
Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
